How Polycystic Kidney Disease Is Managed: Blood Pressure, Monitoring and Complication Care

The ultrasound was ordered for something else entirely, a nagging ache under the ribs that turned out to be a pulled muscle. What the sonographer found instead were two kidneys studded with fluid-filled pockets, the same pattern that had put a father on dialysis in his sixties. The word on the report was one the patient had heard at family gatherings but never applied to herself.

That is how many people first meet polycystic kidney disease: not through symptoms, but through a scan, a blood pressure reading that will not settle, or a relative’s diagnosis that prompts a check. The first question is almost always the same. How is polycystic kidney disease treated, and what can actually be done about a condition written into your genes?

The honest answer is more encouraging than it was a generation ago, and more nuanced than a single prescription. Treatment is a long game built on blood pressure, careful monitoring and swift handling of complications, with a disease-slowing medicine available for some adults. Here is what the evidence supports, and where it runs out.

How is polycystic kidney disease treated? The honest short version

Nothing currently available shrinks polycystic kidneys back to normal or removes the cysts. Every guideline from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to the NHS frames treatment the same way: protect the working kidney tissue you still have, keep blood pressure in a safe range, and deal with complications quickly before they cost you function.

In practice that means a plan with four layers. The foundation is blood pressure control, because high pressure both results from the disease and accelerates it. On top of that sits monitoring: blood tests that estimate how well the kidneys filter, urine tests, and imaging that tracks how fast the kidneys are growing. The third layer is complication care, covering pain, bleeding into cysts, kidney stones, urinary and cyst infections, and problems outside the kidneys such as liver cysts or blood vessel weaknesses. The fourth, for a subset of adults whose disease is judged likely to progress quickly, is a medicine that blocks the hormone vasopressin and has been shown in trials to slow cyst growth and the decline in kidney function.

What treatment looks like for one person may be very different for another. Someone diagnosed at 25 with normal kidney function and no high blood pressure may need little more than yearly checks and lifestyle attention. Someone at 50 with large kidneys and a falling filtration rate is having a conversation about disease-slowing medicine and, eventually, about transplant options. The specialist steering that conversation is a nephrologist, a physician who specializes in kidney disease. Where you sit on that spectrum, and what is offered, is a decision for you and that treating team.

What actually happens inside a polycystic kidney

A healthy kidney contains roughly a million tiny filtering units, each draining into a hair-thin tube. In polycystic kidney disease, a genetic fault makes the cells lining some of those tubes behave abnormally: they multiply too much and pump fluid into a sealed pouch. That pouch is a cyst, a closed sac filled with fluid. According to MedlinePlus, most cases involve faults in one of two genes, PKD1 or PKD2, which normally produce proteins that help tube cells sense fluid flow and stay organized.

A single cyst does no harm. The problem is arithmetic. Cysts form by the hundreds and then thousands, each one enlarging over decades. Together they stretch the kidney, compress the healthy tissue between them, and choke the tiny blood vessels that feed the filtering units. The Mayo Clinic notes that polycystic kidneys can grow to several times their normal size and weigh far more than the roughly fist-sized organs most adults carry. Kidney function often stays surprisingly normal for years because the remaining tissue compensates, then declines once the reserve is used up.

Two hormones matter for treatment. The first is angiotensin, part of a pressure-regulating system that becomes overactive as cysts squeeze blood vessels; this drives the early high blood pressure that most people with ADPKD develop. The second is vasopressin, the hormone that tells kidneys to conserve water. Vasopressin also signals cyst-lining cells to grow and secrete fluid, which is why blocking it became a treatment strategy.

Understanding this mechanism explains the whole management plan. Lower the pressure and you ease the strain on shrinking vessels. Track kidney volume and you get an early warning of how fast the arithmetic is working against you.

What are the different types of polycystic kidney disease, and at what age is it diagnosed?

There are two inherited forms, and they behave very differently. Autosomal dominant polycystic kidney disease (ADPKD) is by far the more common. NIDDK estimates it affects between 1 in 400 and 1 in 1,000 people and accounts for about 5 percent of kidney failure in the United States. “Autosomal dominant” means a single altered gene copy from either parent is enough to cause the disease, so each child of an affected parent has a 50 percent chance of inheriting it. MedlinePlus reports that PKD1 faults account for around 78 percent of cases and PKD2 for around 15 percent; PKD2 disease tends to progress more slowly and reach kidney failure later.

Autosomal recessive polycystic kidney disease (ARPKD) is rare, affecting roughly 1 in 20,000 children according to NIDDK. It requires an altered gene from both parents, who are usually unaffected carriers, and it typically shows up in infancy or even before birth, often alongside liver scarring.

A third pattern, acquired cystic kidney disease, is not inherited at all. Cysts develop in kidneys already damaged by long-standing disease or years of dialysis. It is managed differently and is not the subject of this article.

Age at diagnosis follows the biology. MedlinePlus states that ADPKD signs usually appear between ages 30 and 40, though cysts are present far earlier and a growing number of people are identified in their twenties through family screening or incidental scans. Diagnosis rests mainly on ultrasound, which counts cysts against age-adjusted criteria, with CT or MRI when more detail is needed. Genetic testing is used selectively: when imaging is inconclusive, when family history is absent, or when a relative is considering donating a kidney.

Why blood pressure control comes first when treating polycystic kidney disease

If you remember one thing about how polycystic kidney disease is treated, make it this: blood pressure is the lever with the longest track record. NIDDK notes that high blood pressure develops in most people with ADPKD, often before kidney function falls, and that controlling it can slow the loss of kidney function and reduce the risk of heart disease and stroke, which are the leading causes of death in people with kidney disease generally.

The mechanism is straightforward. Cysts compress the small arteries within the kidney, the kidney responds as though it is starved of blood, and it switches on the angiotensin system that raises pressure throughout the body. That higher pressure then batters the same fragile vessels, and the cycle tightens. Breaking it protects the kidney and everything downstream, including the heart and the brain’s blood vessels.

Targets are individualized, but the American Heart Association defines high blood pressure as 130/80 mm Hg or above and recommends treating to below that level in adults with chronic kidney disease. Some nephrologists aim lower still in younger adults with preserved function, drawing on trial evidence that tighter control was associated with slower kidney growth. Whether that is right for you depends on your age, other conditions, and how you tolerate lower readings.

Home monitoring is a genuine part of treatment, not a hobby. A validated upper-arm cuff, readings taken seated after five quiet minutes, and a simple log shared at appointments give the team far better information than a single reading in a clinic corridor. Reducing sodium, keeping active, limiting alcohol and not smoking each contribute measurable reductions, and the team may adjust medicine based on what your log shows.

Which ADPKD treatment options involve medicine, and how do they work?

Two broad groups of medicine appear in most ADPKD plans, and they do different jobs.

The first group treats blood pressure by calming the overactive angiotensin system. ACE inhibitors and angiotensin receptor blockers (ARBs) are the classes most often chosen, because beyond lowering pressure they reduce strain inside the kidney’s filtering units. NIDDK and the Mayo Clinic both describe these classes as the usual first step. They are not used during pregnancy, and they require a blood test soon after starting to check potassium and kidney function, since a small early shift is expected. Other classes are added if pressure remains high or these are not tolerated.

The second group aims at the disease itself. Tolvaptan, a vasopressin V2 receptor antagonist, blocks the hormone signal that encourages cyst cells to grow and secrete fluid. The NHS describes it as an option for adults with chronic kidney disease whose ADPKD is judged to be progressing rapidly; in trials it slowed kidney enlargement and the rate of decline in kidney function compared with placebo. It does not remove cysts or restore lost function. The trade-offs are real: it causes marked thirst and very frequent urination, including at night, and it can affect the liver, so regular blood tests to monitor liver enzymes are mandatory for as long as it is taken.

Beyond these, treatment is targeted at problems as they arise: antibiotics for infections, pain relief chosen with kidney safety in mind, and medicines to manage the consequences of falling kidney function such as anemia or mineral imbalances. Which options apply to you, and when, is a decision for your prescribing clinician, weighed against your test results and your own priorities.

Who is usually offered disease-slowing medicine, and who is asked to wait

Not everyone with ADPKD is a candidate for vasopressin-blocking treatment, and that is deliberate. The medicine asks a lot of the person taking it, so guidelines reserve it for people whose kidneys are likely to fail sooner without it.

The central concept is “rapid progression.” Nephrologists judge this using several signals: how fast the estimated glomerular filtration rate (eGFR, a blood-test-based estimate of how much the kidneys filter each minute) has fallen over recent years; how large the kidneys are for the person’s age and height, measured as total kidney volume on MRI or CT; the age at which high blood pressure or urinary symptoms first appeared; and family history, particularly relatives reaching kidney failure before 55. The Mayo Clinic describes an imaging classification that sorts kidneys by volume adjusted for height and age to predict future decline.

People typically offered treatment are adults with clear evidence of fast progression and kidney function that is reduced but not yet near failure. People usually asked to wait, or not offered it at all, include those with small kidneys and stable function, those whose kidneys have already failed or are close to it, anyone who is pregnant or planning pregnancy, and people with existing liver disease or who cannot commit to the required blood monitoring.

Waiting is not neglect. Someone with slowly progressing disease may never need this medicine and gains nothing but side effects from starting early. What matters is being re-evaluated at intervals, since a kidney that looks stable at 30 may tell a different story at 40. If your team has said “not now,” it is fair to ask what would change that answer and when the question will be revisited.

Monitoring: what gets checked and how often

Monitoring is where treatment actually happens between appointments. It catches the slow drift in kidney function, flags complications early and tells the team whether the plan is working. Intervals vary by stage and by clinic, so the table below shows typical patterns rather than a schedule to hold anyone to.

What is checked	Why it matters	Typical pattern
Blood pressure (clinic and home)	The strongest modifiable driver of progression	Home readings regularly; reviewed at every visit
eGFR and creatinine (blood)	Tracks filtering capacity and its rate of decline	Yearly when stable; more often as function falls or after medicine changes
Urine albumin and blood	Protein leak and bleeding signal kidney stress or cyst rupture	Yearly, and whenever symptoms change
Potassium, bicarbonate, hemoglobin, calcium, phosphate	Complications of falling function appear here first	Alongside eGFR, more often in later stages
Total kidney volume (MRI or CT)	Predicts speed of progression; guides treatment decisions	At baseline; repeated when a decision depends on it
Liver enzymes	Required safety check on vasopressin-blocking medicine	Regularly for the duration of treatment
Brain vessel imaging (MRA)	Screens for aneurysm in those with family history or high-risk roles	Once, then as advised

Two habits make monitoring more useful. First, keep your own record of eGFR results over time; a single number means little, but a line on a graph shows whether decline is steady, accelerating or flat. Second, tell the team about anything that changed between visits, however small, because a new episode of blood in the urine or a flank ache that lingered may alter what gets ordered next.

Living with pain, bleeding, kidney stones and cyst infections

For many people the day-to-day burden of ADPKD is not the abstract threat of kidney failure but the concrete problems the cysts cause. The Mayo Clinic and NIDDK list the recurring ones: flank or back pain, blood in the urine (hematuria), kidney stones, urinary tract infections and infected cysts.

Pain most often comes from the sheer size of the kidneys pulling on their supporting tissue, or from a cyst that has bled internally or stretched suddenly. Management starts conservatively with heat, rest, posture changes and pain relief chosen for kidney safety. Nonsteroidal anti-inflammatory drugs are generally avoided or used only briefly under advice, because they can reduce blood flow to already stressed kidneys and raise blood pressure. For a single very large cyst causing persistent pain, draining it or a keyhole procedure to unroof it are options some centers offer, though pain frequently returns as other cysts enlarge.

Blood in the urine is common and usually comes from a cyst bleeding into the urinary tract. It often settles within days with rest and fluids, but any first episode, heavy bleeding, or bleeding with fever or clots needs assessment. Recurrent episodes sometimes reflect a stone. NIDDK notes that kidney stones are more common in ADPKD, partly because the distorted drainage system lets urine pool and crystallize; treatment mirrors stone care in anyone else, with the added caution that some procedures are harder in enlarged kidneys.

Infection is the complication that changes the pace. A urinary tract infection is treated as it would be for anyone, but an infected cyst is harder to reach with antibiotics and typically needs a longer course, sometimes with imaging to locate the culprit. Fever with flank pain in someone with ADPKD is treated as urgent until proven otherwise.

Complications beyond the kidneys: liver cysts, aneurysms and heart valves

ADPKD is a whole-body condition wearing a kidney label. The same gene faults affect tube-lining cells elsewhere, so treatment plans account for several sites beyond the kidneys.

Liver cysts are the most frequent. NIDDK describes them as common in ADPKD, more often numerous and larger in women, and usually harmless to liver function because liver tissue, unlike kidney tissue, keeps working around them. When they cause trouble it is by bulk: a distended abdomen, early fullness after meals, breathlessness from pressure on the diaphragm, or pain. Management is symptomatic, with drainage or surgical procedures reserved for severe cases.

Brain aneurysms deserve plain speaking. An aneurysm is a weak, bulging patch in an artery wall that can rupture and cause a bleeding stroke. They occur more often in people with ADPKD than in the general population, and the Mayo Clinic advises screening with magnetic resonance angiography (MRA, a scan of blood vessels) for those with a family history of aneurysm or rupture, and sometimes for people whose occupations make a sudden collapse dangerous. Most aneurysms found are small and monitored rather than treated. Good blood pressure control and not smoking lower the risk of rupture.

Heart valve abnormalities, particularly a floppy mitral valve, are found more often in ADPKD, usually mild and picked up as a murmur. An echocardiogram, an ultrasound of the heart, clarifies the picture; most need only periodic review. Pouches in the bowel wall (diverticula) and abdominal wall hernias are also more common, and cysts occasionally appear in the pancreas or the membranes around the spinal cord.

None of this means every person with ADPKD will face these problems. It means the treating team knows where to look, and you should mention symptoms in these areas rather than assuming they are unrelated.

Diet, water and exercise: what the evidence actually shows

Lifestyle advice for ADPKD is a mix of solid evidence and hopeful theory, and it helps to know which is which.

Sodium restriction is the well-supported part. Less salt lowers blood pressure, which is the best-proven way to protect these kidneys, and NIDDK recommends limiting sodium as a core part of management. Practically, that means reading labels on bread, sauces, deli meats and restaurant food, where most sodium hides, rather than simply skipping the shaker.

Water is where theory outran proof. Because vasopressin drives cyst growth and drinking more suppresses vasopressin, it was long hoped that deliberately high fluid intake would slow the disease. The evidence has not borne that out: a large randomized trial of prescribed high water intake did not show a slower decline in kidney function compared with usual drinking. Staying adequately hydrated remains sensible, especially to reduce stone risk, but drinking to excess is not a treatment and can lower blood sodium in people with reduced kidney function. Ask your team what “enough” means for you.

Protein and potassium advice depends on stage. Early on, a normal balanced diet is usually fine. As function falls, a renal dietitian may suggest moderating protein and adjusting potassium and phosphate based on blood tests, not on generic lists.

Exercise is encouraged. It lowers blood pressure, supports weight management and improves cardiovascular fitness, which matters because heart disease is the main threat in kidney disease. The one caution: enlarged kidneys sit lower and less protected than normal ones, so activities with direct abdominal impact carry a higher risk of cyst bleeding. Smoking accelerates kidney decline and raises aneurysm risk; stopping is one of the highest-yield changes available.

What the first weeks after diagnosis or a new medicine usually look like

The stretch after a diagnosis, or after starting a new treatment, has its own rhythm, and knowing it in advance takes some of the fear out.

After a new diagnosis, the first few weeks are mostly about establishing a baseline. Expect blood tests for eGFR and electrolytes, a urine test, blood pressure measurement, and often a baseline MRI or CT to measure kidney volume. A first nephrology appointment usually covers family history in detail, because how relatives fared is one of the better predictors available. Many people find this period emotionally heavier than any later one; the condition has not changed, but the knowledge is new. Genetic counseling is often offered around this time, both to explain inheritance for children and siblings and to discuss whether testing relatives makes sense.

After starting an ACE inhibitor or ARB, a blood test within the first couple of weeks checks potassium and creatinine. A small rise in creatinine is expected and usually acceptable; a larger one prompts a review. Lightheadedness when standing is common early and typically eases. Blood pressure targets are often reached over several adjustments rather than at once.

Starting a vasopressin-blocking medicine is more disruptive. The NHS notes that thirst and frequent urination begin almost immediately and are largest in the first days, and that regular liver blood tests are scheduled from the outset. People commonly rearrange fluid intake around work and sleep during the first month, and some find the pattern unsustainable, which is a legitimate reason to revisit the decision with the prescriber rather than to stop alone.

By around three months, most treatment plans have settled into their long-term pattern of periodic checks. That steady state, not the anxious first weeks, is what living with ADPKD usually feels like.

When kidneys fail: dialysis, transplant and what shapes polycystic kidney disease life expectancy

Kidney failure is the outcome everyone with ADPKD thinks about, so it deserves clear numbers and clear context. NIDDK reports that about half of people with ADPKD have kidney failure by age 70. Put the other way, half do not, and the age of failure varies widely with which gene is involved, how early blood pressure was controlled, and factors no one fully understands yet.

Life expectancy in ADPKD is therefore not a single figure. It is shaped less by the kidneys themselves than by what kidney disease does to the heart and blood vessels, which is why blood pressure, cholesterol, smoking and diabetes control carry so much weight in the treatment plan. There is no reliable way to predict an individual’s course from a diagnosis alone; the trajectory of eGFR over several years and kidney volume are far more informative than age or symptoms.

When function does fall toward failure, the options are the same as for other kidney diseases. Dialysis, which filters the blood mechanically, can be done through the bloodstream at a center or at home, or through the abdominal lining at home. Very large kidneys or liver can make abdominal dialysis impractical, which is one reason planning starts well before it is needed.

Transplant is widely regarded as offering better quality of life and survival than long-term dialysis for those who are suitable, and people with ADPKD are generally good candidates because the disease does not attack the new kidney. Sometimes one or both enlarged kidneys are removed before or during transplant to make room, a decision made case by case. Relatives who wish to donate are screened for ADPKD first, which is one of the situations where genetic testing earns its place.

What people often get wrong about polycystic kidney disease

Myths cluster around inherited conditions, and ADPKD has collected its share. Correcting them changes decisions.

“If I feel fine, nothing is happening.” The opposite is closer to the truth. Cysts grow for decades before function falls, and blood pressure creeps up silently. Feeling well is not a reason to skip monitoring; it is the window in which monitoring matters most.

“My parent needed dialysis at 55, so I will too.” Family history is informative, but siblings with the same gene fault can reach failure a decade apart. Blood pressure control, smoking status and factors still being studied all shift the timeline. Your own eGFR trend is a better guide than a relative’s story.

“Drinking gallons of water will shrink the cysts.” As discussed above, the trial evidence did not show this. Hydration is sensible; extreme intake is not a treatment.

“The new medicine fixes the disease.” Vasopressin-blocking treatment slows progression in selected adults; it does not remove cysts or restore function, and it brings real side effects. Framing it as a fix leads to disappointment and to people skipping the blood pressure work that helps everyone.

“Cysts are basically tumors.” They are fluid-filled sacs, not cancers. Kidney cancer is not markedly more common in ADPKD, though enlarged, distorted kidneys can make imaging harder to interpret.

“Children can’t be affected.” ADPKD is present from birth even when silent, and ARPKD affects infants directly. Whether and when to screen children is a genuine discussion to have with a genetic counselor, weighing insurance, psychological and practical considerations.

“Once kidneys fail, that’s the end.” Dialysis and transplant are established treatments, and transplant outcomes in ADPKD are generally comparable to those in other kidney diseases.

Questions to ask your care team

A nephrology appointment moves quickly, and the questions that matter most are easy to forget once the numbers start. These are the ones that tend to change what happens next; bring the list and add your own.

• Based on my eGFR trend and kidney volume, how fast does my disease appear to be progressing, and what would change that assessment?
• What blood pressure target are we aiming for, and how should I measure and record it at home?
• Am I a candidate for disease-slowing medicine now? If not, what criteria would make me one, and when will we revisit it?
• Which of my current medicines, including over-the-counter pain relievers and supplements, should I avoid or check with you before taking?
• How much fluid is right for me, and does that change with exercise, heat or any medicine I take?
• Do I need screening for brain aneurysms given my family history or my job?
• Should I have an echocardiogram, and do I need my liver assessed?
• What symptoms should prompt me to call urgently rather than wait for the next appointment?
• How often will my blood and urine be tested, and how will I receive results?
• Would genetic testing help me or my relatives, and is a genetic counselor available?
• If I am considering pregnancy, what changes to my medicines and monitoring would be needed beforehand?
• At what point would we begin planning for transplant or dialysis, and can relatives be assessed as potential donors?
• Is there a kidney dietitian or a patient support service I can be referred to?

Asking is not second-guessing your team. A clinician who has explained the reasoning behind a “not yet” or a particular target has given you something you can act on, and most welcome the chance.

When to call your doctor

Most of ADPKD unfolds slowly, but a handful of situations need same-day attention or emergency care because they signal infection, bleeding, a blocked kidney or a problem in a blood vessel. Contact your care team promptly, or seek emergency care, if you notice any of the following.

• Fever, chills or shaking with pain in your flank or back: this can indicate an infected cyst or kidney infection, which is harder to treat the longer it waits.
• Blood in the urine that is heavy, contains clots, lasts more than a few days, or comes with fever or severe pain.
• Sudden, severe flank or abdominal pain, especially if it follows a fall, a blow or intense exertion, which may mean a cyst has ruptured or bled.
• Pain that spreads toward the groin with nausea or difficulty passing urine, suggesting a kidney stone.
• A sudden, severe headache unlike any you have had before, particularly with neck stiffness, vision changes, weakness or confusion: treat this as an emergency, as it can signal a bleeding aneurysm.
• Blood pressure readings persistently far above your target, or any very high reading with headache, chest pain, breathlessness or blurred vision.
• Passing much less urine than usual, or swelling of the legs, face or abdomen that appears over days.
• If you take vasopressin-blocking medicine: yellowing of the skin or eyes, dark urine, pale stools, unusual tiredness or right-sided upper abdominal pain, which require urgent liver assessment.
• Dizziness, fainting or confusion, especially after starting or changing blood pressure medicine.

None of these is a reason to change or stop a prescribed medicine on your own. The right step is a call, and if the symptom is severe or sudden, emergency services. Your treating team knows your baseline and can tell quickly whether something needs a visit, a test, or simply reassurance.

Frequently asked questions

What is the life expectancy of people with ADPKD?

There is no single life expectancy for ADPKD because the course varies widely between individuals and even within families. NIDDK reports that about half of people with ADPKD reach kidney failure by age 70, while the other half do not. Long-term outlook depends heavily on blood pressure control, heart and blood vessel health, which gene is involved, and access to dialysis or transplant when needed. Your own eGFR trend over several years is a better guide than any general figure.

What are the early symptoms of polycystic kidney disease?

Often there are none, which is why many people are diagnosed through family screening or an unrelated scan. When early signs do occur, MedlinePlus and the Mayo Clinic describe high blood pressure, aching or heaviness in the flank or back, blood in the urine, recurrent urinary infections and kidney stones. These are nonspecific and overlap with many other conditions, so they cannot confirm or rule out ADPKD; imaging and a review of family history by a clinician are needed.

At what age is polycystic kidney disease diagnosed?

ADPKD is most often recognized between ages 30 and 40, when symptoms or high blood pressure first appear, according to MedlinePlus. Cysts are present much earlier, and people with an affected parent are increasingly identified in their twenties through ultrasound screening. The rare recessive form, ARPKD, is usually diagnosed in infancy or before birth. Age at diagnosis does not by itself predict how quickly the disease will progress.

What are the different types of polycystic kidney disease?

Two inherited types exist. Autosomal dominant PKD (ADPKD) is common, needs only one altered gene copy, and usually causes problems in adulthood. Autosomal recessive PKD (ARPKD) is rare, requires an altered gene from both parents, and appears in infancy or childhood, often with liver involvement. A separate, non-inherited pattern called acquired cystic kidney disease develops in kidneys already damaged by long-standing disease or dialysis and is managed differently.

Can polycystic kidney disease be treated with medicine alone?

Medicine is central but not the whole plan. Blood pressure medicines, usually an ACE inhibitor or ARB, protect kidney function, and a vasopressin-blocking medicine can slow progression in selected adults. Neither removes cysts. Monitoring, sodium restriction, not smoking, kidney-safe pain relief and prompt treatment of infections and stones are equally part of treatment, and dialysis or transplant become options if kidney failure develops. Which medicines are right for you is a decision for your prescribing clinician.

What are the main ADPKD treatment options if my kidneys are still working normally?

With normal function, treatment usually centers on prevention and surveillance rather than disease-slowing medicine. That means keeping blood pressure in the target range, checking eGFR and urine yearly, measuring kidney volume to gauge how fast the disease is likely to progress, limiting sodium, avoiding smoking and regular use of nonsteroidal anti-inflammatory drugs, and staying active. Your team will tell you what would change the plan, such as a faster decline or larger kidneys.

Does drinking a lot of water help polycystic kidney disease?

Not as a treatment, according to current trial evidence. The theory was that extra water suppresses vasopressin, the hormone that drives cyst growth, but a large randomized trial of prescribed high water intake did not slow kidney function decline compared with usual drinking. Staying adequately hydrated is still sensible, particularly to reduce kidney stone risk, while excessive intake can lower blood sodium in people with reduced function. Ask your team what amount suits you.

Should I be screened for brain aneurysms if I have ADPKD?

It depends on your risk. The Mayo Clinic advises screening with magnetic resonance angiography for people with ADPKD who have a family history of brain aneurysm or bleeding stroke, and it is sometimes considered for those whose jobs or activities make a sudden collapse dangerous. Routine screening for everyone is not standard. Most aneurysms found are small and monitored rather than treated, and blood pressure control and not smoking lower rupture risk.

Will my children inherit polycystic kidney disease?

For ADPKD, each child of an affected parent has a 50 percent chance of inheriting the altered gene, regardless of sex. For the recessive form, ARPKD, both parents must carry an altered gene, and each pregnancy carries a 25 percent chance of an affected child. Whether and when to screen children is a personal decision with medical, psychological and practical dimensions, and a genetic counselor can help you think it through before any testing.

Can I have a kidney transplant if I have polycystic kidney disease?

Yes, in most cases. People with ADPKD are generally considered good transplant candidates because the disease does not recur in the transplanted kidney, and transplant is widely preferred over long-term dialysis for suitable patients. Occasionally one or both enlarged kidneys are removed to make room. Relatives who wish to donate are first assessed for ADPKD themselves, which is one situation where genetic testing is especially useful. Timing and suitability are decided by your transplant team.

References

• NIDDK (NIH): Polycystic Kidney Disease
• NIDDK (NIH): Autosomal Dominant Polycystic Kidney Disease
• MedlinePlus Genetics: Polycystic kidney disease
• NHS: Autosomal dominant polycystic kidney disease (ADPKD)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.